SII, Department of Biotechnology to launch India's first qHPV vaccine against cervical cancer tomorrow

"It is very effective and prevents cervical cancer because, 85 percent to 90 percent cases, cervical cancer is because of this particular virus and this vaccine is against those viruses," Dr N K Arora

Published On 2022-08-31 09:22 GMT | Update On 2022-08-31 09:22 GMT

New Delhi: The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources told ANI.The most awaited vaccine will be launched by the Union Minister of State (Independent Charge) Science & Technology Jitendra Singh...

New Delhi: The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources told ANI.

The most awaited vaccine will be launched by the Union Minister of State (Independent Charge) Science & Technology Jitendra Singh on Thursday.

According to Dr N K Arora, Chairperson of the COVID working group, National Technical Advisory Group on Immunisation (NTAGI) said it is an exciting experience to launch a made-in-India vaccine.

Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina).

Almost all cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact.

Read also: SII to launch QHPV vaccine against cervical cancer

"It is very exciting and I must say it makes us very happy that our daughters and granddaughters will now be able to get this much-awaited vaccine."

"In fact, this is one of the last major vaccines to be introduced. In fact, this is one of the last vaccines that will be launched in the programme. Now, Indian vaccines will be available and we hope that it will be launched in the National Immunisation programme for 9-14-year-old girls," he added.

Read also: Serum Institute to supply 1 crore qHPV vaccine doses by December: Sources

"It is very effective and prevents cervical cancer because, 85 percent to 90 percent cases, cervical cancer is because of this particular virus and this vaccine is against those viruses. So, if we give it to our young children and daughters, they are protected from the infection and consequently probably 30 years later, cancer does not occur," Dr Arora further explained.

"There was a shortage in the global market. Now Indian vaccine has come. So, we will be able to take care of our requirements within our made-in-India vaccine," he said.

Read also: Centre plans to roll out SII qHPV vaccine for girls aged 9-14 years under National Immunization Programme

Article Source : ANI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SII, Department of Biotechnology to launch India's first qHPV vaccine against cervical cancer tomorrow

"It is very effective and prevents cervical cancer because, 85 percent to 90 percent cases, cervical cancer is because of this particular virus and this vaccine is against those viruses," Dr N K Arora

Similar News